Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten analysts that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $44.71.
A number of research firms have recently weighed in on DNTH. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Wedbush decreased their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Cantor Fitzgerald initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, August 12th.
View Our Latest Research Report on DNTH
Hedge Funds Weigh In On Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
Shares of DNTH stock opened at $25.99 on Wednesday. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The stock has a fifty day moving average price of $28.12 and a 200 day moving average price of $26.11. The stock has a market cap of $762.81 million, a PE ratio of -4.46 and a beta of 1.85.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.32 earnings per share for the current year.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
See Also
- Five stocks we like better than Dianthus Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- P/E Ratio Calculation: How to Assess Stocks
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.